Chimerix (CMRX) News Today $2.81 -0.10 (-3.44%) (As of 12/17/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Chimerix, Inc. (NASDAQ:CMRX) Sees Significant Drop in Short InterestChimerix, Inc. (NASDAQ:CMRX - Get Free Report) was the recipient of a large drop in short interest during the month of November. As of November 30th, there was short interest totalling 647,700 shares, a drop of 8.8% from the November 15th total of 710,300 shares. Approximately 0.8% of the company's shares are sold short. Based on an average daily volume of 3,280,000 shares, the days-to-cover ratio is presently 0.2 days.December 16 at 8:44 PM | marketbeat.comWedbush Has Pessimistic Outlook of Chimerix Q4 EarningsDecember 15 at 1:41 AM | americanbankingnews.comHC Wainwright Has Positive Estimate for Chimerix Q4 EarningsDecember 15 at 1:07 AM | americanbankingnews.comWedbush Comments on Chimerix's Q2 Earnings (NASDAQ:CMRX)December 14, 2024 | americanbankingnews.comWedbush Weighs in on Chimerix's Q4 Earnings (NASDAQ:CMRX)Chimerix, Inc. (NASDAQ:CMRX - Free Report) - Equities researchers at Wedbush cut their Q4 2025 earnings estimates for shares of Chimerix in a research note issued to investors on Tuesday, December 10th. Wedbush analyst D. Nierengarten now anticipates that the biopharmaceutical company will post eDecember 13, 2024 | marketbeat.comHC Wainwright Has Positive Forecast for Chimerix Q4 EarningsChimerix, Inc. (NASDAQ:CMRX - Free Report) - Equities research analysts at HC Wainwright increased their Q4 2024 earnings per share (EPS) estimates for shares of Chimerix in a research report issued on Wednesday, December 11th. HC Wainwright analyst E. White now forecasts that the biopharmaceuticDecember 13, 2024 | marketbeat.comWedbush Has Negative Outlook for Chimerix Q2 EarningsChimerix, Inc. (NASDAQ:CMRX - Free Report) - Stock analysts at Wedbush reduced their Q2 2025 EPS estimates for Chimerix in a research note issued to investors on Monday, December 9th. Wedbush analyst D. Nierengarten now anticipates that the biopharmaceutical company will post earnings of ($0.27)December 12, 2024 | marketbeat.comEdward White’s Buy Rating on Chimerix Driven by Promising Clinical Data and Strategic NDA PlansDecember 11, 2024 | markets.businessinsider.comChimerix's (CMRX) "Buy" Rating Reaffirmed at HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $11.00 price target on shares of Chimerix in a research report on Wednesday.December 11, 2024 | marketbeat.comChimerix (NASDAQ:CMRX) Earns Outperform Rating from WedbushDecember 11, 2024 | americanbankingnews.comInvestors Look Ahead to Key Inflation Data as US Futures Tread Water in Tuesday's PremarketDecember 10, 2024 | msn.comSmall Cap Soars On FDA Submission PlansDecember 10, 2024 | theglobeandmail.comTD Cowen Reaffirms Their Buy Rating on Chimerix (CMRX)December 10, 2024 | markets.businessinsider.comChimerix Soars 220% on FDA Filing Plans for Lifesaving Brain Cancer TherapyDecember 10, 2024 | finance.yahoo.comChimerix Stock Draws Heavy Retail Chatter After Landing Price-Target Hike On FDA Submission Plan For Cancer DrugDecember 10, 2024 | msn.comChimerix to submit dordaviprone NDA to FDA, seeks accelerated approvalDecember 9, 2024 | markets.businessinsider.comChimerix Shares Top 52-week Highs, Company Plans FDA Submission of Cancer Drug DordaviproneDecember 9, 2024 | marketwatch.comChimerix to Submit Dordaviprone for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-EndDecember 9, 2024 | globenewswire.comChimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)December 6, 2024 | globenewswire.comChimerix IncNovember 26, 2024 | money.usnews.comChimerix (NASDAQ:CMRX) Given Outperform Rating at WedbushWedbush restated an "outperform" rating and issued a $6.00 price target on shares of Chimerix in a research report on Monday.November 18, 2024 | marketbeat.comChimerix, Inc. (NASDAQ:CMRX) Short Interest UpdateChimerix, Inc. (NASDAQ:CMRX - Get Free Report) was the recipient of a significant drop in short interest in the month of October. As of October 31st, there was short interest totalling 1,520,000 shares, a drop of 12.6% from the October 15th total of 1,740,000 shares. Approximately 1.9% of the shares of the company are sold short. Based on an average daily trading volume, of 460,100 shares, the short-interest ratio is currently 3.3 days.November 17, 2024 | marketbeat.comChimerix’s Phase 2 Reassessment Boosts Buy Rating Amid Promising Data and Strong FinancialsNovember 12, 2024 | markets.businessinsider.comChimerix announces updates Phase 2 data at 2024 SNO meetingNovember 11, 2024 | markets.businessinsider.comChimerix’s Dordaviprone Shows Promising Efficacy in H3 K27M-mutant Diffuse Glioma with $11 Price TargetNovember 11, 2024 | markets.businessinsider.comChimerix (NASDAQ:CMRX) Earns Buy Rating from HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $11.00 price objective on shares of Chimerix in a report on Monday.November 11, 2024 | marketbeat.comChimerix, Inc.: Chimerix Announces Updated Phase 2 Response Assessment of Dordaviprone in Recurrent H3 K27M Glioma at the 2024 SNO MeetingNovember 11, 2024 | finanznachrichten.deChimerix Announces Updated Phase 2 Response Assessment of Dordaviprone in Recurrent H3 K27M Glioma at the 2024 SNO MeetingNovember 11, 2024 | markets.businessinsider.comChimerix’s Strategic Regulatory Progress and Market Potential Bolster Buy RatingNovember 8, 2024 | markets.businessinsider.comChimerix Inc (CMRX) Q3 2024 Earnings Call Highlights: Strategic Advancements Amid Financial ...November 8, 2024 | finance.yahoo.comChimerix, Inc. (CMRX) Q3 2024 Earnings Call TranscriptNovember 7, 2024 | seekingalpha.comChimerix Inc (CMRX) Q3 2024: Everything You Need to Know Ahead of EarningsNovember 6, 2024 | finance.yahoo.comChimerix (CMRX) Scheduled to Post Quarterly Earnings on ThursdayChimerix (NASDAQ:CMRX) will be releasing earnings before the market opens on Thursday, November 7, Zacks reports.November 2, 2024 | marketbeat.comChimerix (NASDAQ:CMRX) Shares Cross Above Two Hundred Day Moving Average - Here's WhyChimerix (NASDAQ:CMRX) Stock Price Crosses Above 200 Day Moving Average - What's Next?November 2, 2024 | marketbeat.comChimerix to Report Third Quarter 2024 Financial Results and Provide an Operational Update on November 7, 2024November 1, 2024 | globenewswire.comChimerix (NASDAQ:CMRX) Share Price Passes Below Two Hundred Day Moving Average - What's Next?Chimerix (NASDAQ:CMRX) Stock Passes Below Two Hundred Day Moving Average - What's Next?October 25, 2024 | marketbeat.comChimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)October 18, 2024 | globenewswire.comChimerix (NASDAQ:CMRX) Stock Quotes, Forecast and News SummaryOctober 11, 2024 | benzinga.comChimerix (NASDAQ:CMRX) Share Price Passes Above 200-Day Moving Average - What's Next?Chimerix (NASDAQ:CMRX) Stock Price Passes Above 200-Day Moving Average - Time to Sell?October 5, 2024 | marketbeat.comHere's Why We're Watching Chimerix's (NASDAQ:CMRX) Cash Burn SituationSeptember 23, 2024 | finance.yahoo.comChimerix (NASDAQ:CMRX) Shares Pass Below 200 Day Moving Average of $0.95Chimerix (NASDAQ:CMRX) Shares Cross Below 200-Day Moving Average of $0.95September 20, 2024 | marketbeat.comChimerix (NASDAQ:CMRX) Share Price Passes Below 200 Day Moving Average of $0.96Chimerix (NASDAQ:CMRX) Shares Pass Below 200 Day Moving Average of $0.96September 12, 2024 | marketbeat.comChimerix to Present at H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 3, 2024 | markets.businessinsider.comChimerix (NASDAQ:CMRX) Shares Cross Below 200 Day Moving Average of $0.97Chimerix (NASDAQ:CMRX) Share Price Crosses Below Two Hundred Day Moving Average of $0.97September 3, 2024 | marketbeat.comChimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)August 30, 2024 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Chimerix (CMRX) and Ocuphire Pharma (OCUP)August 22, 2024 | markets.businessinsider.comChimerix Inc (CXF.DU)August 21, 2024 | uk.finance.yahoo.comShort Interest in Chimerix, Inc. (NASDAQ:CMRX) Expands By 18.1%Chimerix, Inc. (NASDAQ:CMRX - Get Free Report) was the target of a significant increase in short interest in July. As of July 31st, there was short interest totalling 1,890,000 shares, an increase of 18.1% from the July 15th total of 1,600,000 shares. Based on an average daily volume of 213,100 shares, the days-to-cover ratio is presently 8.9 days. Currently, 2.4% of the company's stock are short sold.August 16, 2024 | marketbeat.comChimerix, Inc. (NASDAQ:CMRX) Expected to Post Q1 2025 Earnings of ($0.24) Per ShareChimerix, Inc. (NASDAQ:CMRX - Free Report) - Stock analysts at Wedbush dropped their Q1 2025 earnings estimates for Chimerix in a note issued to investors on Tuesday, August 13th. Wedbush analyst D. Nierengarten now expects that the biopharmaceutical company will post earnings of ($0.24) per sharAugust 16, 2024 | marketbeat.comEquities Analysts Offer Predictions for Chimerix, Inc.'s FY2028 Earnings (NASDAQ:CMRX)Chimerix, Inc. (NASDAQ:CMRX - Free Report) - Equities researchers at Capital One Financial reduced their FY2028 EPS estimates for shares of Chimerix in a research note issued on Tuesday, August 13th. Capital One Financial analyst N. Quibria now forecasts that the biopharmaceutical company will eaAugust 15, 2024 | marketbeat.com Get Chimerix News Delivered to You Automatically Sign up to receive the latest news and ratings for CMRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Musk threatens Liberal’s fake “energy crisis” (Ad)Elon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies. To get the full details on the fake “energy crisis” of America, watch this now CMRX Media Mentions By Week CMRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CMRX News Sentiment▼0.220.72▲Average Medical News Sentiment CMRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CMRX Articles This Week▼202▲CMRX Articles Average Week Get Chimerix News Delivered to You Automatically Sign up to receive the latest news and ratings for CMRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Avadel Pharmaceuticals News Today Septerna News Today Collegium Pharmaceutical News Today Bicara Therapeutics News Today Zymeworks News Today Gyre Therapeutics News Today Cogent Biosciences News Today Poseida Therapeutics News Today Phibro Animal Health News Today Nuvation Bio News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CMRX) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredMissed Nvidia? Buy Elon Musk’s “Silent Partner”In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my f...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chimerix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Chimerix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
